Literature DB >> 1521518

Surgical management of acromegaly.

R Fahlbusch1, J Honegger, M Buchfelder.   

Abstract

Surgery is generally the primary therapy of choice in acromegaly, and the predominantly used transsphenoidal approach has proved to be efficient and safe. Surgical results are dependent on preoperative tumor size and extension and preoperative growth hormone levels. Invasion appears to be the most important factor in predicting surgical outcome. Growth hormone levels can be normalized in 71% of all cases and in more than 80% of microadenomas. Persistent growth hormone excess may require reoperation, radiotherapy, or medical treatment. With close interdisciplinary cooperation of neurosurgeons, endocrinologists, and radiotherapists, nearly all acromegalic patients can be successfully treated today.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1521518

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  31 in total

1.  Determinants of neurosurgical outcome in pituitary tumors.

Authors:  M J Barahona; L Sojo; A M Wägner; F Bartumeus; B Oliver; P Cano; S M Webb
Journal:  J Endocrinol Invest       Date:  2005-10       Impact factor: 4.256

2.  The time course of visual field recovery following transphenoidal surgery for pituitary adenomas: predictive factors for a good outcome.

Authors:  K K Gnanalingham; S Bhattacharjee; R Pennington; J Ng; N Mendoza
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-03       Impact factor: 10.154

3.  Endoscopic endonasal transsphenoidal approach: an additional reason in support of surgery in the management of pituitary lesions.

Authors:  P Cappabianca; A Alfieri; A Colao; D Ferone; G Lombardi; E de Divitiis
Journal:  Skull Base Surg       Date:  1999

4.  Pituitary Macroadenoma and Visual Impairment: Postoperative Outcome Prediction with Contrast-Enhanced FIESTA.

Authors:  S Hisanaga; S Kakeda; J Yamamoto; K Watanabe; J Moriya; T Nagata; Y Fujino; H Kondo; S Nishizawa; Y Korogi
Journal:  AJNR Am J Neuroradiol       Date:  2017-09-14       Impact factor: 3.825

5.  Factors predicting pituitary adenoma invasiveness in acromegalic patients.

Authors:  A Rieger; N G Rainov; H Ebel; L Sanchin; K Shibib; C Helfrich; O Hoffmann; W Burkert
Journal:  Neurosurg Rev       Date:  1997       Impact factor: 3.042

6.  Acromegaly: treatment after 100 years.

Authors:  J A Wass
Journal:  BMJ       Date:  1993-12-11

7.  Lanreotide 60 mg, a longer-acting somatostatin analog: tumor shrinkage and hormonal normalization in acromegaly.

Authors:  R Cozzi; M Barausse; M Sberna; A Lodrini; A Franzini; G Lasio; R Attanasio
Journal:  Pituitary       Date:  2000-12       Impact factor: 4.107

8.  Cost-of-illness study in acromegalic patients in Italy.

Authors:  G Didoni; S Grottol; V Gasco; M Battistini; D Ferone; M Giusti; F Ragazzoni; P Ruffo; E Ghigo; F Minuto
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

Review 9.  Management of acromegaly: is there a role for primary medical therapy?

Authors:  Zachary M Bush; Mary Lee Vance
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

10.  Improvement of acromegaly after octreotide LAR treatment.

Authors:  Ruth Mangupli; Aponte Lisette; Contreras Ivett; Camperos Paul; Cruz de los Ríos Victoria; Cevallos Jose Luis
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.